Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DANCER Trial: Rituximab Dose-Ranging in RA
NCT00074438Phase 2Completed
- Sponsor
- Genentech
- Start
- Jun 2003
- Primary completion
- Sep 2004
- Modality
- Monoclonal Antibodies
01
Overview
Phase 2, randomised, double-blind trial of rituximab in rheumatoid arthritis (RA) (9 arms), sponsored by Genentech. Primary endpoint: American College of Rheumatology 20% Response at 24 weeks. Started Jun 2003; status: completed.
02
Drugs
rituximab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT00074438.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00074438.